These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 28502135)
1. Systemic Lupus Erythmatosus is Associated with Disturbed Cytokine Milieu and Increased TNF-Related Apoptosis-Induced Ligand Levels. Saeed AM; Mogahed MM Egypt J Immunol; 2016 Jun; 23(2):75-85. PubMed ID: 28502135 [TBL] [Abstract][Full Text] [Related]
2. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310 [TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Sabry A; Sheashaa H; El-Husseini A; Mahmoud K; Eldahshan KF; George SK; Abdel-Khalek E; El-Shafey EM; Abo-Zenah H Cytokine; 2006 Aug; 35(3-4):148-53. PubMed ID: 17027280 [TBL] [Abstract][Full Text] [Related]
4. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Mahmoud RA; El-Gendi HI; Ahmed HH Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275 [TBL] [Abstract][Full Text] [Related]
5. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Rus V; Zernetkina V; Puliaev R; Cudrici C; Mathai S; Via CS Clin Immunol; 2005 Oct; 117(1):48-56. PubMed ID: 15961346 [TBL] [Abstract][Full Text] [Related]
6. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. Wais T; Fierz W; Stoll T; Villiger PM J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506 [TBL] [Abstract][Full Text] [Related]
7. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099 [TBL] [Abstract][Full Text] [Related]
8. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective? Gómez D; Correa PA; Gómez LM; Cadena J; Molina JF; Anaya JM Semin Arthritis Rheum; 2004 Jun; 33(6):404-13. PubMed ID: 15190525 [TBL] [Abstract][Full Text] [Related]
9. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Miret C; Molina R; Filella X; García-Carrasco M; Claver G; Ingelmo M; Ballesta A; Font J Tumour Biol; 2003; 24(4):185-8. PubMed ID: 14654712 [TBL] [Abstract][Full Text] [Related]
10. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Sabry A; Elbasyouni SR; Sheashaa HA; Alhusseini AA; Mahmoud K; George SK; Kaleek EA; abo-Zena H; Kalil AM; Mohsen T; Rahim MA; El-samanody AZ Int Urol Nephrol; 2006; 38(3-4):731-7. PubMed ID: 17260180 [TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Studnicka-Benke A; Steiner G; Petera P; Smolen JS Br J Rheumatol; 1996 Nov; 35(11):1067-74. PubMed ID: 8948291 [TBL] [Abstract][Full Text] [Related]
12. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. Arora V; Verma J; Marwah V; Kumar A; Anand D; Das N Lupus; 2012 May; 21(6):596-603. PubMed ID: 22300832 [TBL] [Abstract][Full Text] [Related]
13. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus. Brink I; Thiele B; Burmester GR; Trebeljahr G; Emmrich F; Hiepe F Lupus; 1999; 8(9):723-30. PubMed ID: 10602444 [TBL] [Abstract][Full Text] [Related]
14. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Robak E; Sysa-Jedrzejewska A; Dziankowska B; Torzecka D; Chojnowski K; Robak T Arch Immunol Ther Exp (Warsz); 1998; 46(6):375-80. PubMed ID: 9883317 [TBL] [Abstract][Full Text] [Related]
15. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810 [TBL] [Abstract][Full Text] [Related]
16. The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. McCarthy EM; Smith S; Lee RZ; Cunnane G; Doran MF; Donnelly S; Howard D; O'Connell P; Kearns G; Ní Gabhann J; Jefferies CA Rheumatology (Oxford); 2014 Sep; 53(9):1586-94. PubMed ID: 24706988 [TBL] [Abstract][Full Text] [Related]